How we know · 12 dated events
GLP-1 market timeline
Every regulatory action, approval, trial result and coverage change that moved this market, with the date it happened and a link to our coverage. Newest first. Entries are added rather than rewritten, so the log stays an audit trail rather than a summary.
Each date below was verified against published reporting on . Where we could establish a month but not a day, the entry says so.
Dated events
GLP-1 product-liability MDL reaches 3,928 cases
Per JPML figures published 3 August 2026. The consolidated Zepbound and GLP-1 proceeding stood at 3,848 lawsuits as of 1 July 2026.
FDA comment period closes on 503B bulks exclusion
The window for comment on permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list closed. No final determination has been announced.
Medicare GLP-1 Bridge goes live
First Medicare coverage of weight-loss medication. Runs to 31 December 2027, costs Medicare about $245 a month per patient, caps the beneficiary copay at $50.
FDA extends the 503B comment period by 30 days
Published in the Federal Register after a request for additional time, moving the close from late June to 30 July.
FDA issues 25 warning letters to GLP-1 telehealth firms
Sent during the week of 15 June over allegedly false or misleading promotional claims about compounded GLP-1 products.
Retatrutide reports Phase 3 topline above 28%
Eli Lilly reported positive topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial. Retatrutide remains investigational and unapproved.
503B bulks proposal opens in the Federal Register
Sixty-day comment window opens on the FDA's proposal to exclude the three molecules from the 503B bulks list.
FDA proposes excluding GLP-1s from the 503B bulks list
The agency announced it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances.
Orforglipron approved as Foundayo
The first oral small-molecule, non-peptide GLP-1 receptor agonist approved for weight management. Around 12% weight loss at the top dose. Date shown is the approval month; we have not captured a precise day.
FDA declares the semaglutide shortage resolved
Ends the shortage-era basis for compounding copies of the approved product. Wind-down dates for 503A pharmacies and 503B facilities followed.
FDA declares the tirzepatide shortage resolved
The first of the two resolutions that ended large-scale lawful compounding of copies.
Zepbound approved for obstructive sleep apnea
Creates a coverage pathway for patients who do not qualify on obesity alone. Some plans now cover it on that basis.
How often this is updated
The price dataset is re-verified in capture rounds and every figure carries its own date; the current version is v2026-08-11. This timeline is updated when a material event occurs — an FDA action, an approval, a trial readout, or a coverage change — rather than on a fixed schedule, because a timeline padded to hit a cadence stops being a timeline.
Two things we know are coming and will be added the day they land: the FDA's final determination on the 503B bulks list, and the FDA response on CagriSema expected during 2026.
Questions
When did the FDA declare the GLP-1 shortages over?
The tirzepatide shortage was declared resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025. Those two dates ended the shortage-era basis for compounding copies of the approved products.
When did Medicare start covering weight-loss drugs?
The Medicare GLP-1 Bridge went live on 1 July 2026 and runs through 31 December 2027, with a maximum $50 monthly beneficiary copay.
What is the next event to watch?
The FDA's final determination on excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — the comment period closed on 30 July 2026 — and the FDA response on CagriSema expected during 2026.